Galenicum

What Galenicum does

Galenicum Health, S.L.U. is a Barcelona-based specialty pharmaceutical company founded in 2003 that operates as an integrated ecosystem spanning the full pharmaceutical value chain. Starting as an Active Pharmaceutical Ingredient (API) trading business serving generic companies in Spain, the company progressively expanded into formulation R&D, regulatory affairs, contract manufacturing, and branded distribution. Today Galenicum operates through four core business units: Galenicum Axium (development, licensing, and global supply of APIs and finished dosage forms through B2B partnership models), Galenicum SAG (manufacturing at a state-of-the-art facility near Madrid with capacity exceeding 50 million packs per year across liquids, ointments, creams, sachets, powders, nasal sprays, tablets, and hard gelatin capsules), Galenicum Vitae (sales and distribution of bioequivalent medicines under the Vitae brand in Latin America, Asia, and the Middle East), and Galenicum Derma (specialty dermatological products marketed in Spain via a direct sales team).

The company generated €213 million in consolidated revenue and €300 million in aggregated revenue in 2023, with 14% year-over-year growth and a projected 27% growth rate for the following year. Approximately 52% of revenue is derived from exports, with commercial agreements spanning about 70 countries. The business model combines multiple revenue streams: B2B pharmaceutical product licensing and supply agreements (quote-based, multi-year contracts), contract manufacturing services, and direct commercialization of proprietary brands. Notable recent moves include a January 2026 licensing and supply agreement with Lupin Atlantis Holdings SA covering injectable Semaglutide (GLP-1 receptor agonist) for Type 2 diabetes and weight management across 23 countries, positioning the company in one of the highest-growth therapeutic categories.

Galenicum is founder-controlled following a September 2021 minority investment by London-based Peninsula Capital, which acquired a 20% stake while founders retained majority ownership and operational control. The company holds ISO 14001 (environmental management) and ISO 45001 (occupational health and safety) certifications, is GDPR compliant, and demonstrates an 82% product launch success rate. With 800+ employees globally (87% based in Spain, 54% women), the company maintains dedicated offices in Barcelona (headquarters and R&D), Madrid-area (manufacturing), Chile, Peru, Colombia, Ecuador, Mexico, and India, alongside distribution partnerships spanning Latin America, Asia, and the Middle East.

Name

Galenicum

Legal name

Galenicum Health, S.L.U.

Website

https://galenicum.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

251–500 employees

Short description

Galenicum Health, S.L.U. is a Barcelona-based specialty pharmaceutical company founded in 2003 that operates an integrated ecosystem covering API trading, formulation R&D, contract manufacturing, and branded distribution across approximately 70 countries through four business units (Axium, SAG, Vitae, Derma).

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Generic pharmaceuticals manufacturing
• Pharmaceutical contract manufacturing
• API trading supply
• Bioequivalent medicines development
• Pharmaceutical licensing partnerships

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. B2B Pharmaceutical Products: Trading of Active Pharmaceutical Ingredients (APIs) and pharmaceutical products to generic companies and pharmaceutical laboratories worldwide through partnership agreements and licensing deals.
2. Manufacturing Services: Contract manufacturing of pharmaceutical products in multiple formats with production capacity of over 50 million packs per year, serving both own portfolio and third-party clients.
3. Own Brand Products - Vitae: Sales and distribution of bioequivalent medicines under own brand 'Vitae' through affiliates in Latin American markets and distribution partners across Asia and Middle East.
4. Own Brand Products - Galenicum Derma: Sales of specialty dermatological products under own brand 'Galenicum Derma' through sales team covering Spain national market.
5. Licensing and Supply Agreements: Development, manufacturing, and supply partnerships where Galenicum provides finished formulations while partners handle regulatory submissions and commercialization across global markets.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Galenicum develops, manufactures, and globally supplies pharmaceutical products across the full industry value chain — from API trading through R&D, regulatory affairs, manufacturing, and worldwide distribution. The company operates four business units: Galenicum Axium (development, licensing and supply of pharmaceutical products to other pharma companies), Galenicum SAG (contract manufacturing with 50+ million packs/year capacity across multiple dosage formats), Galenicum Vitae (own-brand bioequivalent medicines sold in Latin America, Asia and Middle East), and Galenicum Derma (specialty dermatological products sold in Spain). Products span most therapeutic areas and dosage forms including tablets, capsules, nasal sprays, injectables, creams, ointments, sachets, and powders.

Product overview

Galenicum is a specialty pharmaceutical company founded in Barcelona in 2003, operating as an ecosystem of several businesses that covers the entire pharmaceutical industry value chain. The company consists of four main business units: Galenicum Axium (development, licensing and supply of pharmaceutical products worldwide), Galenicum SAG (manufacturing of pharmaceutical products with over 50 million packs per year capacity), Galenicum Vitae (sales and distribution of bioequivalent medicines under the 'Vitae' brand in Latin America, Asia and Middle East), and Galenicum Derma (specialty dermatological products under the 'Galenicum Derma' brand). The company offers a broad portfolio of high-quality APIs and Finished Dosage Forms covering most therapeutic areas and technologies including liquids, ointments, creams, sachets, powders, nasal sprays, tablets and hard gelatin capsules. Commercial agreements span more than fifty countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Galenicum Axium: Development, licensing and supply of pharmaceutical products worldwide with multiple partnership models.
• Galenicum SAG
• Galenicum Vitae
• Galenicum Derma

Products and services

• Galenicum Axium

Quantifiable outcome

• 14% revenue growth year-over-year
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Lupin Atlantis Holdings SAcoreOEM/ Whitelabel/ Licensing Partner · 21 January 2026Licensing and supply agreement for injectable Semaglutide, a GLP-1 receptor agonist for Type 2 diabetes and weight management. Galenicum handles development, manufacturing, and supply while Lupin manages regulatory submissions, approvals, and commercialization across 23 countries including Canada, Europe, Southeast Asia, and Latin America. The partnership positions both companies to capitalize on the growing global GLP-1 market ahead of patent expiry.

Scale indicators15 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• Lupin Limited: Indian-headquartered global generic and specialty pharmaceutical major, named partner for Galenicum's Semaglutide program and directly overlapping on generic Finished Dosage Forms, API supply and multi-country commercialization across Latin America, Europe and Southeast Asia.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with broad Finished Dosage Form portfolio, API capabilities and global commercial reach, structurally comparable to Galenicum's Axium/SAG/Vitae mix across multiple therapeutic categories.
• Dr. Reddy's Laboratories: Global generics and API player with manufacturing across multiple dosage forms, licensing partnerships and emerging-market commercial presence — directly comparable in business model to Galenicum's B2B and own-brand structure.
• Curia Global (formerly AMRI): Contract development and manufacturing organization (CDMO) with API and Finished Dosage Form capabilities for multiple dosage forms, structurally similar to Galenicum SAG's contract manufacturing business serving B2B pharma partners.
• Cambrex: Specialty CDMO focused on small-molecule API and Finished Dosage Form manufacturing across multiple formats, a close functional comparator to Galenicum SAG's contract manufacturing offering.
• Zydus Lifesciences: Indian-headquartered integrated pharmaceutical manufacturer combining API, formulations and branded generics distribution with strong emerging-market presence, broadly comparable to Galenicum's multi-unit model.
• Apotex: Canadian-headquartered generics manufacturer with broad Finished Dosage Form portfolio, API capability and international distribution; comparable to Galenicum's mid-sized generic/specialty pharma footprint and licensing-driven go-to-market.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer, with broad Finished Dosage Form manufacturing, API capabilities and global commercialization spanning dermatology, CNS and specialty categories where Galenicum also competes.
• Viatris: Global generics and biosimilars powerhouse formed from Mylan/Pfizer Upjohn, with extensive multi-country commercial reach, broad API capability and a portfolio strategy that mirrors Galenicum's Vitae/Derma structure at much larger scale.
• STADA Arzneimittel: European-headquartered generics, specialty pharma and consumer healthcare company, often cited as a comparable European specialty pharma with manufacturing and multi-region branded generics distribution similar to Galenicum.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/galenicum-health

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galenicum